Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1.336,50 GBX | -0,67% |
|
+3,28% | -0,74% |
17/04 | GSK zegt dat Health Canada uitgebreide Jemperli indicatie goedkeurt | MT |
17/04 | GSK zegt dat Health Canada goedkeuring Jemperli Plus chemotherapie uitbreidt | RE |
Beschrijving van de bedrijfsactiviteiten: GSK plc
Aantal werknemers: 68.629
Verdeling van verkoop per activiteit: GSK plc
Start boekjaar: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Commercial Operations | - | - | 29,32 mld. | 30,33 mld. | 31,38 mld. |
Corporate and Other Unallocated Turnover | 28 mln. | - | - | - | - |
Consumer Healthcare | 10,03 mld. | 9,61 mld. | - | - | - |
Vaccines | 6,98 mld. | 6,78 mld. | - | - | - |
Pharmaceuticals | 17,06 mld. | 17,73 mld. | - | - | - |
Geografische uitsplitsing van de verkoop: GSK plc
Start boekjaar: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States (US) | 14,56 mld. | 15,09 mld. | 14,54 mld. | 15,82 mld. | 16,38 mld. |
Rest of World | 18,56 mld. | 18,05 mld. | 14,09 mld. | 13,82 mld. | 14,28 mld. |
United Kingdom (UK) | 980 mln. | 975 mln. | 695 mln. | 693 mln. | 708 mln. |
Uitvoerend comité: GSK plc
Bedrijfsleider | Titel | Leeftijd | Van |
---|---|---|---|
Emma Walmsley
CEO | Algemeen Directeur | 56 | 01-04-2017 |
Julie Brown
DFI | Financieel Directeur/CFO | 63 | 01-05-2023 |
James Ford
CMP | Compliance Officer | - | 01-08-2018 |
Hoofd Techniek/Wetenschap/O&O | - | 01-12-2021 | |
Tony Wood
CTO | Hoofd Techniek/Wetenschap/O&O | - | 19-01-2022 |
Samenstelling van de raad van bestuur: GSK plc
Directeur | Titel | Leeftijd | Van |
---|---|---|---|
Emma Walmsley
BRD | Directeur/Bestuurslid | 56 | 01-01-2017 |
Jesse Goodman
BRD | Directeur/Bestuurslid | 73 | 01-01-2016 |
Hal Barron
BRD | Directeur/Bestuurslid | 63 | 01-01-2018 |
Jonathan Symonds
CHM | Voorzitter | 67 | 01-09-2019 |
Charles Bancroft
BRD | Directeur/Bestuurslid | 66 | 01-05-2020 |
Anne Beal
BRD | Directeur/Bestuurslid | 63 | 06-05-2021 |
Harry Dietz
BRD | Directeur/Bestuurslid | 67 | 01-01-2022 |
Vishal Sikka
BRD | Directeur/Bestuurslid | 58 | 18-07-2022 |
Directeur/Bestuurslid | 67 | 01-09-2022 | |
Julie Brown
BRD | Directeur/Bestuurslid | 63 | 01-05-2023 |
Participaties: GSK plc
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
127.054.524 | 75% | 4.277.094.886 $ | |
263.029.794 | 82,59% | 392.685.070 $ | |
HALEON PAKISTAN LIMITED 85,79% | 100.423.259 | 85,79% | 282.410.289 $ |
16.775.691 | 11% | 135.547.583 $ | |
GLAXOSMITHKLINE S.A.E 91,2% | 76.161.378 | 91,2% | 59.591.709 $ |
VIR BIOTECHNOLOGY, INC. 6,21% | 8.550.954 | 6,21% | 55.410.182 $ |
CUREVAC N.V. 7,4% | 16.591.937 | 7,4% | 45.959.665 $ |
421.984 | 6,45% | 28.485.709 $ | |
DONG-A ST CO., LTD. 7,87% | 736.456 | 7,87% | 22.031.162 $ |
LYELL IMMUNOPHARMA, INC. 10,35% | 30.253.189 | 10,35% | 16.276.216 $ |
Bedrijfsgegevens: GSK plc

Bedrijven van de groep: GSK plc
Naam | Categorie en sector |
---|---|
GlaxoSmithKline IHC Ltd.
![]() GlaxoSmithKline IHC Ltd. Regional BanksFinance Part of GSK Plc, GlaxoSmithKline IHC Ltd. provides banking services. The company is based in Middlesex, UK. |
Regional Banks
|
GlaxoSmithKline Holdings (Ireland) Ltd.
![]() GlaxoSmithKline Holdings (Ireland) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, GlaxoSmithKline Holdings (Ireland) Ltd. provides financial management services. The company is based in Brentford, UK. Founded in 2014. |
Miscellaneous Commercial Services
|
GSK Consumer Healthcare Capital US LLC
![]() GSK Consumer Healthcare Capital US LLC Finance/Rental/LeasingFinance Part of Haleon Plc, Haleon US Capital LLC is a company that provides healthcare services. Haleon US Capital LLC is based in Wilmington, DE. |
Finance/Rental/Leasing
|
GlaxoSmithKline Trading Services Ltd.
![]() GlaxoSmithKline Trading Services Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Trading Services Ltd. is an Irish company that manufactures and wholesales pharmaceutical products. The company is based in Dublin, Ireland. |
Pharmaceuticals: Major
|
GlaxoSmithKline Insurance Ltd. |
Farmaceutische producten - Andere
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Varia. 1j. | Varia. 3j. | Kapi.($) | |
---|---|---|---|---|---|---|
-0,67% | +3,28% | -16,42% | -39,24% | 71,88 mld. | ||
+14,30% | +14,68% | +15,65% | +182,81% | 754 mld. | ||
+2,31% | +3,78% | +6,46% | -13,99% | 379 mld. | ||
+0,76% | -1,18% | +3,95% | +10,64% | 306 mld. | ||
-1,03% | +0,23% | -51,37% | +6,55% | 285 mld. | ||
+0,47% | +4,84% | +15,08% | -32,25% | 250 mld. | ||
+0,19% | +5,27% | +5,96% | +4,06% | 210 mld. | ||
-1,27% | +1,16% | -7,51% | -3,58% | 208 mld. | ||
+2,01% | -1,49% | -37,99% | -9,08% | 196 mld. | ||
-1,89% | -3,04% | +3,11% | +9,44% | 149 mld. | ||
Gemiddelde | +1,52% | +4,32% | -6,31% | +11,54% | 281,14 mld. | |
Gewogen gemiddelde per kap. | +4,11% | +6,74% | -1,39% | +45,01% |
Sector
